Hereditary diffuse gastric cancer is a tumor predisposition syndrome primarily caused by heterozygous pathogenic variants in the CDH1 gene. It is inherited in an autosomal dominant pattern and increases the risk of diffuse gastric cancer in both sexes and breast lobular carcinoma in women. Loss of function of E-cadherin reduces adhesion between epithelial cells and favors their dispersed infiltration.
Hereditary diffuse gastric cancer (CDH1 gene)
The CDH1 gene encodes E-cadherin, a transmembrane protein essential for adherens junctions, cell polarity, and epithelial organization. Its extracellular domain connects neighboring cells, while its intracellular region binds to catenins and the cytoskeleton, also participating in pathways that regulate cell migration and proliferation.
Affected individuals inherit an altered copy of CDH1 and the tumor appears when the second functional copy is inactivated in specific cells through a somatic variant, loss of heterozygosity, or promoter methylation. The absence of E-cadherin results in poorly cohesive cells, often with a signet-ring morphology, which distribute in small foci throughout the gastric mucosa and can infiltrate the wall without forming an obvious mass. Penetrance is incomplete and varies among families; current estimates indicate that risk is largely dependent on family history. Founder variants have been described in Māori, Newfoundland, and northern Portuguese populations.
Symptoms
Initial foci are usually microscopic and asymptomatic, which makes endoscopic detection difficult. When the cancer progresses, epigastric pain, early satiety, nausea, loss of appetite and weight, dysphagia, anemia, or digestive bleeding may appear. The average age of diagnosis is approximately between 42 and 49 years, although cases have been described since adolescence. In women, lobular breast carcinoma usually manifests in adulthood and can be bilateral.
Disease management
There is no pharmacological treatment that completely prevents tumor development. In carriers of pathogenic or likely pathogenic variants in CDH1, risk-reducing total gastrectomy can be considered from early adulthood, after an individual assessment in an expert unit. If surgery is postponed or not performed, periodic endoscopic surveillance with multiple directed and random biopsies is recommended, recognizing that it may not detect all microscopic foci. Helicobacter pylori infections should also be investigated and treated. In women, specific breast monitoring is advised, usually with annual magnetic resonance imaging from age 30 and mammography according to age; risk-reducing mastectomy can be individually assessed. After a gastrectomy, lifelong nutritional follow-up is required.
Genes analyzed
Bibliography
Barbosa-Matos R, Córdova L, Schrader K, et al. Diffuse Gastric and Lobular Breast Cancer Syndrome. GeneReviews®. Updated in 2024.
Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386-e397.
Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 Variants and Lifetime Cancer Risk. JAMA. 2024;332(9):722-729.
Luo X, Maciaszek JL, Thompson BA, et al. Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines. J Med Genet. 2023;60(6):568-575.
